FDA Moves to Ban Long-Unused Orange Skin Dye
Published Date: 7/23/2026
Proposed Rule
Summary
The FDA wants to stop allowing Citrus Red No. 2 to be used on orange skins because it hasn’t been used since 2020. This change affects orange growers and food companies but won’t cost anyone money since the color additive is already out of use. If you have thoughts, you’ve got until August 24, 2026, to speak up!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Existing certificates to cease; depletion window offered
If the final order is issued, certificates for any existing batches of Citrus Red No. 2 would cease to be effective on the rule's effective date (90 days after publication — publication was July 23, 2026, so the effective date would be October 21, 2026), and use after that date would render the food adulterated. FDA proposes to refrain from enforcing the final order for up to one year after the effective date (until October 21, 2027) to allow holders to deplete any remaining certified supply.
FDA proposes repeal of Citrus Red No. 2
The FDA is proposing to revoke the rule (21 CFR 74.302) that allows Citrus Red No. 2 to be used on the skins of mature oranges. FDA records show Citrus Red No. 2 has not been batch certified for use in U.S. food since 2020, and the agency states the listing appears abandoned and removing it will not cost anyone money because the additive is already out of use.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14898, FDA's Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development
The FDA is rolling out a new plan to speed up how drugs and biologics are made and tested, especially for serious diseases that need fast solutions. This affects drug makers who want to bring treatments to patients quicker by improving the chemistry, manufacturing, and controls process. Starting now through 2027, these changes aim to save time and help get important medicines to people faster without extra costs.
2026-14910, Revocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages
The FDA is officially banning the use of the color additive Orange B on frankfurter and sausage casings because it’s no longer used or needed. This change affects food makers who color these meats and takes effect on September 8, 2026. If anyone disagrees, they have until August 24, 2026, to speak up—no extra costs or surprises, just a cleaner, clearer food color rule!
2026-14779, Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.
2026-14573, Food Standards of Identity Modernization; Pasteurized Orange Juice
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
Previous / Next Documents
Previous: 2026-14906, Rescinding Portions of AmeriCorps Title VI Regulations To Conform More Closely With the Statutory Text and To Implement Executive Order 14281
AmeriCorps is updating its rules to match the original Civil Rights Act by removing parts that punish unintentional discrimination. This change affects organizations working with AmeriCorps, making compliance simpler and avoiding legal issues. Comments are open until August 24, 2026, so now’s the time to weigh in!
Next: 2026-14917, Electronic Disclosure by Group Health Plans Under ERISA
Group health plans can soon share important info online instead of paper, making it easier and cheaper for everyone. If this rule passes, plan administrators must notify members about electronic disclosures but still offer paper copies if requested. This change affects anyone in group health plans under ERISA and aims to save time and money starting after the rule is finalized.